Search research articles
Contact Us
Filters
Showing results (31-40 of 114) with videos related to
Page
of 12
Sort By:
Translational Oncology
|
February 6, 2017
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Rosaria Chilà, Terence Hall G, Giovanni Abbadessa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2003
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin
Maria Antonietta Sabatino, Tina Colombo, Cristina Geroni, et al.
Molecular Cancer Therapeutics
|
October 27, 2011
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown
Sara Previdi, Giovanni Abbadessa, Francesca Dalò, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2005
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs
Faina Vikhanskaya, Mobin M Siddique, Ming Kei Lee, et al.
Frontiers in Oncology
|
June 20, 2022
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Michela Chiappa, Serena Petrella, Giovanna Damia, et al.
American Journal of Cancer Research
|
June 9, 2012
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
Elisa Caiola, Eliana Rulli, Robert Fruscio, et al.
Oncotarget
|
June 11, 2016
Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
Elisa Caiola, Laura Brunelli, Mirko Marabese, et al.
Plos One
|
November 22, 2013
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model
Sara Previdi, Federica Scolari, Rosaria Chilà, et al.
Anti-Cancer Drugs
|
April 20, 2004
Brostallicin: a new concept in minor groove DNA binder development
Massimo Broggini, Sergio Marchini, Erminia Fontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 14, 2008
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil
Monica Ganzinelli, Laura Carrassa, Francesca Crippa, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 114) with videos related to
Sort By:
Page
of 12
Translational Oncology
|
February 6, 2017
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Rosaria Chilà, Terence Hall G, Giovanni Abbadessa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2003
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin
Maria Antonietta Sabatino, Tina Colombo, Cristina Geroni, et al.
Molecular Cancer Therapeutics
|
October 27, 2011
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown
Sara Previdi, Giovanni Abbadessa, Francesca Dalò, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2005
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs
Faina Vikhanskaya, Mobin M Siddique, Ming Kei Lee, et al.
Frontiers in Oncology
|
June 20, 2022
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Michela Chiappa, Serena Petrella, Giovanna Damia, et al.
American Journal of Cancer Research
|
June 9, 2012
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
Elisa Caiola, Eliana Rulli, Robert Fruscio, et al.
Oncotarget
|
June 11, 2016
Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
Elisa Caiola, Laura Brunelli, Mirko Marabese, et al.
Plos One
|
November 22, 2013
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model
Sara Previdi, Federica Scolari, Rosaria Chilà, et al.
Anti-Cancer Drugs
|
April 20, 2004
Brostallicin: a new concept in minor groove DNA binder development
Massimo Broggini, Sergio Marchini, Erminia Fontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 14, 2008
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil
Monica Ganzinelli, Laura Carrassa, Francesca Crippa, et al.
Page
of 12